Oncology Pipeline | Takeda Cancer Drug Development
Our Oncology Pipeline
Our research and development efforts focus on advancing medicines for hematologic, thoracic and gastrointestinal cancers. These therapies in development are investigational and have not been approved by any regulatory bodies for use in the investigational indications listed below.
Click + for additional information
Investigational therapy | Modality | Investigational indication | Phase | ||
Mirvetuximab soravtansine-gynx (TAK-853) (Japan rights only) | |||||
ADC | Folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer | Filed | |||
ADC | Folate receptor alpha (FRα)-positive platinum-sensitive ovarian cancer | Phase 3 | |||
Rusfertide (TAK-121) | |||||
Small molecule | Polycythemia vera | Filed | |||
Elritercept (TAK-226) | |||||
Complex biologic | 2L anemia-associated myelodysplastic syndromes | Phase 3 | |||
Complex biologic | Anemia-associated myelofibrosis | Phase 2 | |||
TAK-928 | |||||
Complex biologic | 2L squamous non-small cell lung cancer | Phase 3 | |||
Complex biologic | Solid tumors | Phase 2 | |||
TAK-921 | |||||
ADC | 3L+ gastric cancer | Phase 3 | |||
ADC | Solid tumors | Phase 1 | |||
TAK-188 | |||||
ADC | Solid tumors | Phase 1/2 | |||
TAK-168 | |||||
Small molecule | Solid tumors | Phase 1 |